enGene Holdings Inc. Common Stock
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGen… Read more
enGene Holdings Inc. Common Stock (ENGN) - Total Assets
Latest total assets as of January 2026: $337.11 Million USD
Based on the latest financial reports, enGene Holdings Inc. Common Stock (ENGN) holds total assets worth $337.11 Million USD as of January 2026.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
enGene Holdings Inc. Common Stock - Total Assets Trend (2021–2025)
This chart illustrates how enGene Holdings Inc. Common Stock’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
enGene Holdings Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (October 2025)
enGene Holdings Inc. Common Stock's total assets of $337.11 Million consist of 90.9% current assets and 9.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 22.7% |
| Accounts Receivable | $2.23 Million | 1.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how enGene Holdings Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: enGene Holdings Inc. Common Stock's current assets represent 90.9% of total assets in 2025, an increase from 1.2% in 2021.
- Cash Position: Cash and equivalents constituted 22.7% of total assets in 2025, up from 0.8% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 1.0% of total assets.
enGene Holdings Inc. Common Stock Competitors by Total Assets
Key competitors of enGene Holdings Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
enGene Holdings Inc. Common Stock - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - enGene Holdings Inc. Common Stock generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, enGene Holdings Inc. Common Stock generates $ 52.97 in net profit.
enGene Holdings Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.75 | 17.16 | 4.79 |
| Quick Ratio | 11.75 | 17.16 | 4.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $264.61 Million | $ 209.37 Million | $ 1.24 Million |
enGene Holdings Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between enGene Holdings Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.80 |
| Latest Market Cap to Assets Ratio | 0.87 |
| Asset Growth Rate (YoY) | -28.8% |
| Total Assets | $221.47 Million |
| Market Capitalization | $191.67 Million USD |
Valuation Analysis
Near Book Valuation: The market values enGene Holdings Inc. Common Stock's assets close to their book value ( 0.87x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: enGene Holdings Inc. Common Stock's assets decreased by 28.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for enGene Holdings Inc. Common Stock (2021–2025)
The table below shows the annual total assets of enGene Holdings Inc. Common Stock from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-10-31 | $221.47 Million | -28.83% |
| 2024-10-31 | $311.17 Million | +257.84% |
| 2023-10-31 | $86.96 Million | -34.14% |
| 2022-10-31 | $132.04 Million | +0.45% |
| 2021-10-31 | $131.45 Million | -- |